These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Human Leukocyte Antigen Class I Antibodies and Response to Platelet Transfusion in Patients Undergoing Liver Transplantation. Wong M, Narra R, Selim M, Zimmerman MA, Kim J, Padmanabhan A, Hong JC. J Surg Res; 2020 Nov; 255():99-105. PubMed ID: 32543385 [Abstract] [Full Text] [Related]
5. Analysis of platelet-reactive alloantibodies and evaluation of cross-match-compatible platelets for the management of patients with transfusion refractoriness. Wang J, Xia W, Deng J, Xu X, Shao Y, Ding H, Chen Y, Liu J, Chen D, Ye X, Santoso S. Transfus Med; 2018 Feb; 28(1):40-46. PubMed ID: 28516675 [Abstract] [Full Text] [Related]
7. Human Leukocyte Antigen Alloimmunization and Alloimmune Platelet Refractoriness. Saris A, Pavenski K. Transfus Med Rev; 2020 Oct; 34(4):250-257. PubMed ID: 33127210 [Abstract] [Full Text] [Related]
8. [Platelet allo-antibodies identification strategies for preventing and managing platelet refractoriness]. Basire A, Picard C. Transfus Clin Biol; 2014 Nov; 21(4-5):193-206. PubMed ID: 25277423 [Abstract] [Full Text] [Related]
9. HLA-Mediated Platelet Refractoriness. Schmidt AE, Refaai MA, Coppage M. Am J Clin Pathol; 2019 Mar 01; 151(4):353-363. PubMed ID: 30285067 [Abstract] [Full Text] [Related]
10. Platelet transfusion refractoriness and anti-HLA immunization. Blandin L, Dougé A, Fayard A, Bay JO, Berlie G, Pereira B, Lemal R, Rouzaire P. Transfusion; 2021 Jun 01; 61(6):1700-1704. PubMed ID: 33709433 [Abstract] [Full Text] [Related]
11. Platelet transfusion refractoriness due to HLA alloimmunization: Evolving paradigms in mechanisms and management. Panch SR, Guo L, Vassallo R. Blood Rev; 2023 Nov 01; 62():101135. PubMed ID: 37805287 [Abstract] [Full Text] [Related]
15. C1q-binding anti-HLA antibodies do not predict platelet transfusion failure in Trial to Reduce Alloimmunization to Platelets study participants. Jackman RP, Lee JH, Pei R, Bolgiano D, Lebedeva M, Slichter SJ, Norris PJ. Transfusion; 2016 Jun 01; 56(6):1442-50. PubMed ID: 27079754 [Abstract] [Full Text] [Related]
19. Anti-HLA Class I alloantibodies in platelet transfusion refractoriness: From mechanisms and determinants to therapeutic prospects. Couvidou A, Rojas-Jiménez G, Dupuis A, Maître B. Front Immunol; 2023 Jul 01; 14():1125367. PubMed ID: 36845153 [Abstract] [Full Text] [Related]
20. Human leukocyte antigen (HLA)-incompatible mean fluorescence intensity-selected platelet products have corrected count increments similar to HLA antigen-matched platelets. Karafin MS, Schumacher C, Zhang J, Simpson P, Johnson ST, Pierce KL. Transfusion; 2021 Aug 01; 61(8):2307-2316. PubMed ID: 34075590 [Abstract] [Full Text] [Related] Page: [Next] [New Search]